Search Results - "Haering, Dieter A"

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response by Kuhle, Jens, Kropshofer, Harald, Haering, Dieter A, Kundu, Uma, Meinert, Rolf, Barro, Christian, Dahlke, Frank, Tomic, Davorka, Leppert, David, Kappos, Ludwig

“…OBJECTIVETo assess the value of blood neurofilament light chain (NfL) as a biomarker of recent, ongoing, and future disease activity and tissue damage and its…”
Get full text

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS by Sormani, Maria Pia, Haering, Dieter A., Kropshofer, Harald, Leppert, David, Kundu, Uma, Barro, Christian, Kappos, Ludwig, Tomic, Davorka, Kuhle, Jens

“…Objectives To assess whether neurofilament light chain (NfL) could serve as an informative endpoint in Phase 2 studies in patients with relapsing–remitting…”
Get full text

Learning ability correlates with brain atrophy and disability progression in RRMS by Sormani, Maria Pia, De Stefano, Nicola, Giovannoni, Gavin, Langdon, Dawn, Piani-Meier, Daniela, Haering, Dieter A, Kappos, Ludwig, Tomic, Davorka

“…ObjectiveTo assess the prognostic value of practice effect on Paced Auditory Serial Addition Test (PASAT) in multiple sclerosis.MethodsWe compared screening…”
Get full text

Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS by Cohen, Jeffrey A., Barkhof, Frederik, Comi, Giancarlo, Izquierdo, Guillermo, Khatri, Bhupendra, Montalban, Xavier, Pelletier, Jean, Eckert, Benjamin, Häring, Dieter A., Francis, Gordon

“…In the 12-month phase 3 TRANSFORMS study, fingolimod showed greater efficacy than intramuscular interferon beta (IFNβ)-1a in patients with relapsing–remitting…”
Get full text

How patients with multiple sclerosis acquire disability by Lublin, Fred D, Häring, Dieter A, Ganjgahi, Habib, Ocampo, Alex, Hatami, Farhad, Čuklina, Jelena, Aarden, Piet, Dahlke, Frank, Arnold, Douglas L, Wiendl, Heinz, Chitnis, Tanuja, Nichols, Thomas E, Kieseier, Bernd C, Bermel, Robert A

“…Patients with multiple sclerosis acquire disability either through: (1) Relapse-associated worsening (RAW), or (2) progression independent of relapse activity…”
Get full text

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis by Kappos, Ludwig, De Stefano, Nicola, Freedman, Mark S, Cree, Bruce AC, Radue, Ernst-Wilhelm, Sprenger, Till, Sormani, Maria Pia, Smith, Terence, Häring, Dieter A, Piani Meier, Daniela, Tomic, Davorka

“…Background: ‘No evidence of disease activity’ (NEDA), defined as absence of magnetic resonance imaging activity (T2 and/or gadolinium-enhanced T1 lesions),…”
Get full text

Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis by Gaetano, Laura, Häring, Dieter A, Radue, Ernst-Wilhelm, Mueller-Lenke, Nicole, Thakur, Avinash, Tomic, Davorka, Kappos, Ludwig, Sprenger, Till

“…OBJECTIVETo study the effect of fingolimod on deep gray matter (dGM), thalamus, cortical GM (cGM), white matter (WM), and ventricular volume (VV) in patients…”
Get full text

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial by Lublin, Fred, Prof, Miller, David H, Prof, Freedman, Mark S, Prof, Cree, Bruce A C, Prof, Wolinsky, Jerry S, Prof, Weiner, Howard, Prof, Lubetzki, Catherine, Prof, Hartung, Hans-Peter, Prof, Montalban, Xavier, Prof, Uitdehaag, Bernard M J, Prof, Merschhemke, Martin, MD, Li, Bingbing, PhD, Putzki, Norman, MD, Liu, Fonda C, PharmD, Häring, Dieter A, PhD, Kappos, Ludwig, Prof

“…Summary Background No treatments have been approved for primary progressive multiple sclerosis. Fingolimod, an oral sphingosine 1-phosphate receptor modulator,…”
Get full text

Reader Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis by Kropshofer, Harald, Häring, Dieter A., Kappos, Ludwig, Leppert, David, Kuhle, Jens

Get full text

Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II by Gärtner, Jutta, Hauser, Stephen L, Bar-Or, Amit, Montalban, Xavier, Cohen, Jeffrey A, Cross, Anne H, Deiva, Kumaran, Ganjgahi, Habib, Häring, Dieter A, Li, Bingbing, Pingili, Ratnakar, Ramanathan, Krishnan, Su, Wendy, Willi, Roman, Kieseier, Bernd, Kappos, Ludwig

“…Background: In the phase III ASCLEPIOS I and II trials, participants with relapsing multiple sclerosis receiving ofatumumab had significantly better clinical…”
Get full text

Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis by Radue, Ernst-Wilhelm, Barkhof, Frederik, Kappos, Ludwig, Sprenger, Till, Häring, Dieter A, de Vera, Ana, von Rosenstiel, Philipp, Bright, Jeremy R, Francis, Gordon, Cohen, Jeffrey A

“…OBJECTIVE:We investigated the determinants and clinical correlations of MRI-detected brain volume loss (BVL) among patients with relapsing-remitting multiple…”
Get full text

Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis by Langdon, Dawn W., Tomic, Davorka, Penner, Iris‐Katharina, Calabrese, Pasquale, Cutter, Gary, Häring, Dieter A., Dahlke, Frank, Kappos, Ludwig

“…Background and purpose Studies reporting the baseline determinants of cognitive performance and treatment effect on cognition in patients with multiple…”
Get full text

Prognostic Value of Serum NfL for Subclinical Disease Activity and Worsening in Patients with RMS: Results from the Phase 3 ASCLEPIOS I and II Trials (4069) by Ziemssen, Tjalf, Arnold, Douglas L., Alvarez, Enrique, Cross, Anne H., Willi, Roman, Li, Bingbing, Kukkaro, Petra, Kropshofer, Harald, Ramanathan, Krishnan, Merschhemke, Martin, Su, Wendy, Haering, Dieter A., Hauser, Stephen L., Kappos, Ludwig, Kuhle, Jens

“…Abstract only…”
Get full text

Comparable Ofatumumab Treatment Outcomes in Patients across Racial/Ethnic Groups in the ASCLEPIOS I/II and APOLITOS studies (4139) by Delgado, Silvia R., Williams, Mitzi J., Bagger, Morten, Graham, Gordon, Pigeolet, Etienne, Yu, Huixin, Haering, Dieter A., Willi, Roman, Kerloeguen, Cecile, Xu, Chao, Hirano, Masaru, Stoneman, Dee, Su, Wendy, Ramanathan, Krishnan, Nakahara, Jin

“…Abstract only…”
Get full text

Application of a convolutional neural network to the quality control of MRI defacing by Delbarre, Daniel J., Santos, Luis, Ganjgahi, Habib, Horner, Neil, McCoy, Aaron, Westerberg, Henrik, Häring, Dieter A., Nichols, Thomas E., Mallon, Ann-Marie

“…Large-scale neuroimaging datasets present unique challenges for automated processing pipelines. Motivated by a large clinical trials dataset with over 235,000…”
Get full text

Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study by Kira, Jun-ichi, Nakahara, Jin, Sazonov, Denis V, Kurosawa, Takayoshi, Tsumiyama, Isao, Willi, Roman, Zalesak, Martin, Pingili, Ratnakar, Häring, Dieter A, Ramanathan, Krishnan, Kieseier, Bernd C, Merschhemke, Martin, Su, Wendy, Saida, Takahiko

“…Background: Ofatumumab, the first fully human anti-CD20 monoclonal antibody, has been developed as a treatment for relapsing multiple sclerosis (RMS) which can…”
Get full text

Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis by Samjoo, Imtiaz A, Worthington, Evelyn, Drudge, Christopher, Zhao, Melody, Cameron, Chris, Häring, Dieter A, Stoneman, Dee, Klotz, Luisa, Adlard, Nicholas

“…To compare the efficacy of ofatumumab to other disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS). A network meta-analysis was conducted…”
Get full text

Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis by Samjoo, Imtiaz A, Drudge, Christopher, Walsh, Sarah, Tiwari, Santosh, Brennan, Róisín, Boer, Ibolya, Häring, Dieter A, Klotz, Luisa, Adlard, Nicholas, Banhazi, Judit

“…To assess the relative efficacy of disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS) including newer therapies (ozanimod, ponesimod,…”
Get full text

Comment on “Fingolimod effects on left ventricular function in multiple sclerosis” Mult Scler 2015 by Bakshi, Rajesh, Häring, Dieter A

Get full text

Systematic review and network meta‐analysis comparing ofatumumab with other disease‐modifying therapies available in Japan for the treatment of patients with relapsing multiple sclerosis by Drudge, Christopher, Zhao, Melody, Tanaka, Satoru, Tanaka, Nozomu, Otaka, Hiromichi, Kawachi, Izumi, Häring, Dieter A., Brennan, Róisín, Adlard, Nicholas, Samjoo, Imtiaz A.

“…Objective No head‐to‐head clinical trials have compared ofatumumab with other disease‐modifying therapies (DMTs) available in Japan for patients with relapsing…”
Get full text